Welcome to the Pacific Edge Investor Centre. Here you will find useful information about being a shareholder of our company.
See the latest news and presentations, keep up to date with our newsletters and shareholder reports, find out when we are holding shareholder meetings and check up on our share price.
Pacific Edge is a publicy listed company on the NZX: listed as PEB.
- Value $00,000.000
- Volume 00,000
- Capitalisation $000,000
- Open $0.000
- Close $0.000
- High $0.000
- Low $0.000
Data up to date as of 00-00-0000 00:00
Full Suite of Cxbladder Tests Adopted by NZ Public Healthcare Provider Capital & Coast DHB
Pacific Edge signs agreement with Capital & Coast District Health Board, providing access to full suite of Cxbladder products [read more]
Cxbladder Commercial Evaluation by Johns Hopkins Medicine
Cancer diagnostics company, Pacific Edge, advises that Johns Hopkins Medicine has commenced their commercial evaluation of Cxbladder, the company’s non-invasive molecular diagnostic test for the detection and management of bladder cancer, with a number of urologists at the institution. [read more]
Pacific Edge Receives Notification of Cxbladder National CMS Reimbursement Rate in the USA
Cancer diagnostics company, Pacific Edge (NZX: PEB) is pleased to advise that the preliminary national CMS reimbursement rate of US$760 (NZ$ 1,166) has been publicly notified. The national reimbursement rate covers the Cxbladder tests awarded national CPT codes in the USA earlier this year, [read more]
Reports and Presentations
For further investor information on Pacific Edge our recent annual reports, investor presentations and investment research reports are available for download below
FY18 Full Year Results Conference Call Audio Commentary[9.6 MB]
FY18 Full Year Results Presentation[733 KB]